Natera, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Natera, Inc. (NTRA) is a global leader in cell-free DNA (cfDNA) testing, specializing in noninvasive molecular diagnostics for oncology, women's health, and organ health. Founded in 2004 and headquartered in Austin, Texas, the company operates CAP-accredited and CLIA-certified laboratories in Austin, Texas, and San Carlos, California, with a global presence including facilities in the Netherlands and partnerships extending services to numerous countries worldwide. Natera leverages proprietary technology combining novel molecular biology and bioinformatics to detect genetic material from blood samples, enabling early risk assessment, recurrence detection, and personalized treatment decisions for clinicians and patients. The company's core offerings span women's health tests including Panorama, a non-invasive prenatal test (NIPT) screening for fetal chromosomal abnormalities such as Down syndrome with positive predictive value reporting; Horizon, advanced carrier screening for hundreds of genetic conditions; Vistara, single-gene NIPT for 25 additional conditions; Anora, a miscarriage analysis test; Spectrum, preimplantation genetic testing for IVF embryos; and Empower for hereditary cancer risk. In oncology, Natera provides Signatera, a personalized circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) monitoring, recurrence detection, and treatment response evaluation across cancers like colorectal, bladder, lymphoma, and multiple myeloma; Altera for tumor genomic profiling to identify somatic mutations and clinical trials; Latitude, a tissue-free MRD test; and Empower for germline mutations. Organ health solutions feature Prospera, a donor-derived cfDNA test for kidney transplant rejection assessment. Recent developments include the launch of Signatera Genome, a genome-designed MRD assay achieving Medicare coverage; Latitude Tissue-Free MRD; Fetal Focus single-gene NIPT with an expanded version forthcoming; and a Panorama vanishing twin workflow. Natera raised its 2025 revenue guidance to $2.18-$2.26 billion following strong Q3 2025 results with record revenues and oncology test volume growth of 46.1% year-over-year, alongside plans for seven new MolDX submissions potentially worth $250-$300 million in gross profit. Strategic partnerships with BGI Genomics Co., Ltd. and Foundation Medicine, Inc. enhance genetic testing capabilities and market expansion in precision medicine, while new data from trials like IMvigor011 and upcoming presentations at the 2025 American Society of Hematology meeting underscore ongoing clinical validation.
Company News
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
Natera (NASDAQ:NTRA) Hits New 12-Month High – Here’s Why
3 Analysts, 3 Trades to Make Today
Uber, Micron, Datadog And A Health Care Stock: CNBC's ‘Final Trades'
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript
Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Natera CEO Steven Chapman Sells 1,698 Shares for $545,000
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters.
Arizona State Retirement System Purchases 2,899 Shares of Natera, Inc. $NTRA
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)
Why Moderna's Cancer Vaccine Matters to Investors
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
Caisse de depot et placement du Quebec Buys New Shares in Natera, Inc. $NTRA
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™